Spirogen

LATEST NEWS

New Publication - SG2274 Gene-Targeting AgentFri 4th Jul 08

Latest publication: Kotecha M. et al. (2008). Inhibition of DNA binding of the NF-Y transcriptio

More information »

LATEST PRESS RELEASE

Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000Thu 8th Oct 09

London, United Kingdom, 08 October, 2009 - Spirogen Limited (Spirogen), the UK-based developer of DN

More information »

A clinical stage Biotechnology company creating potent small molecules based on novel mechanisms and chemistry to target important cancers.

The company has significant experience utilizing cutting edge technologies to make effective DNA sequence targeted agents.